NASDAQ · Healthcare · Biotechnology
Ligand Pharmaceuticals Incorporated
LGND
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. CEO Todd C. Davis · Market cap $6.1B.
$303.59
+7.67 · +2.59%
52w hi $305.7152w lo $111.72
Off 52w high 4.1%
48
ROUTINE
Current InsiderScore
Corp · 90d
1
0 buys · 1 sales
Cong · 90d
1
1 buys · 0 sales
Signals ≥ 60 · 12mo
0
0 strong · 0 notable
Analyst consensus
Strong Buy
Avg PT $249.33
Section 01
Recent Form 4 filings
6 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Jun 11 | Jason Aryeh | Sell | 4,500 | $250.00 | −$1.13M | 22 | |
| May 09 | Todd C Davis | Chief Executive Officer | Buy | 5,523 | $105.67 | +$584K | 58 |
| May 09 | Octavio Espinoza | Chief Financial Officer | Buy | 1,000 | $103.89 | +$104K | 52 |
| May 09 | Todd C Davis | Chief Executive Officer | Buy | 1,680 | $104.57 | +$176K | 55 |
| May 09 | Todd C Davis | Chief Executive Officer | Buy | 2,307 | $104.53 | +$241K | 55 |
| May 09 | Octavio Espinoza | Chief Financial Officer | Buy | 500 | $104.40 | +$52K | 49 |
Section 02
Recent STOCK Act disclosures
3 disclosures on file
| Disclosed | Legislator | Chamber · State | Action | Range | Midpoint | Delay | Score |
|---|---|---|---|---|---|---|---|
| Jun 09 | Gilbert Cisneros | House · CA | Buy | $1,001 - $15,000 | $8K | 11 d | 48 |
| Feb 13 | Gilbert Cisneros | House · CA | Buy | $1,001 - $15,000 | $8K | 29 d | 44 |
| Feb 13 | Gilbert Cisneros | House · CA | Buy | $1,001 - $15,000 | $8K | 39 d | 40 |
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JulAugSepOctNovDecJanFebMarAprMayJun